AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Geovax Labs Keeps 'Buy' Rating with $9 Price Target
ByAinvest
Thursday, Jul 17, 2025 3:32 pm ET1min read
Geovax Labs (GOVX) maintains a "Buy" rating and price target of $9.00 USD from D. Boral Capital's analyst Jason Kolbert. The company's strong position in the market is reflected in the consistent rating and unchanged price target. The average one-year price target from 5 analysts is $10.70, with an upside of 1,356.77% from the current price. The average brokerage recommendation is 2.0, indicating an "Outperform" status.
Title: GeoVax Labs (GOVX): Analysts Maintain Positive Outlook Despite Recent Stock PerformanceJuly 2, 2025 - Despite recent fluctuations in its stock price, GeoVax Labs (GOVX) continues to attract positive analyst ratings. D. Boral Capital's analyst Jason Kolbert maintains a "Buy" rating and a price target of $9.00 USD for the company. This consistent rating reflects GeoVax Labs' strong market position and potential for growth.
The average one-year price target from five analysts stands at $10.70, indicating an impressive upside potential of 1,356.77% from the current price. The average brokerage recommendation is 2.0, which translates to an "Outperform" status. This consensus suggests that analysts believe in the company's long-term prospects.
However, recent market performance has shown mixed signals. According to a technical analysis report [1], GOVX has several negative signals and is within a falling trend, making it a "Strong Sell" candidate. The stock price ended at $0.7345 on July 16, 2025, after rising 6.38% from $0.6958. The technical indicators lean more towards a neutral outlook in the mid-term.
GeoVax Labs' recent focus on accelerating the development of its GEO-MVA vaccine candidate, supported by the European Medicines Agency's streamlined development pathway, is expected to bolster its market position. The company is actively engaging with global health authorities to expand access to its Mpox vaccine candidate, addressing the growing urgency of global outbreaks [2].
Despite the recent stock performance, analysts remain optimistic about GeoVax Labs' future. The company's strong IP portfolio and lead clinical programs, including its GEO-CM04S1 vaccine and Gedeptin® oncolytic therapy, position it as a key player in the biotechnology sector.
References:
[1] https://intellectia.ai/stock/GOVX/forecast
[2] https://www.nasdaq.com/press-release/geovax-highlights-growing-urgency-diversified-mpox-vaccine-supply-global-outbreaks
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet